Your browser doesn't support javascript.
loading
Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
He, Jimmy Zhijian; Duval, Vincent; Jauslin, Petra; Gonçalves, Antonio; Abegesah, Aburough; Fan, Chunling; Lim, KyoungSoo; Song, Xuyang; Chen, Cecil; Shi, Xiaojin; Mann, Helen; Krug, Lee; Ren, Song; Phipps, Alex; Gibbs, Megan; Zhou, Diansong.
Afiliación
  • He JZ; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Duval V; Certara, Integrated Drug Development, Basel, Switzerland.
  • Jauslin P; Certara, Integrated Drug Development, Basel, Switzerland.
  • Gonçalves A; Certara, Integrated Drug Development, Basel, Switzerland.
  • Abegesah A; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Fan C; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Lim K; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Song X; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Chen C; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, South San Francisco, California, USA.
  • Shi X; Oncology R&D, Late-Stage Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Mann H; Oncology Biometrics, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Krug L; Oncology R&D, Late-Stage Development, AstraZeneca, New York, New York, USA.
  • Ren S; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Phipps A; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Gibbs M; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
  • Zhou D; Clinical Pharmacology & Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts, USA.
Clin Pharmacol Ther ; 114(6): 1375-1386, 2023 12.
Article en En | MEDLINE | ID: mdl-37777827
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Clin Pharmacol Ther Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos